We interpret these data to mean that damaging mutations in ERCC2 (XPD) contribute to conferring tumor advantage in patients with medium levels of mutational burden, particularly in those affected by carcinomas of the bladder, renal pelvis, and ureter. This evidence concerns the gene ERCC2 and urinary bladder carcinoma.